SPORE in Lymphoma

来自罗切斯特大学詹姆斯·P·威尔莫特癌症中心（JPWCC）和亚利桑那大学亚利桑那癌症中心（ACC）的淋巴瘤孢子应用程序提供了一个基础广泛的转化研究计划，研究淋巴瘤生物学中几个主要未解决的问题。具体而言，这些项目将集中在几种新型的，有针对性的治疗药物，无论是在开发或批准用于治疗三种最常见的非霍奇金淋巴瘤，即弥漫性大B细胞淋巴瘤，滤泡性淋巴瘤和套细胞淋巴瘤。我们将首先在体外和精心开发的模型系统中寻求阐明作用和/或耐药性机制;然后设计并进行以相关研究为重点的试点临床试验，以验证这些机制。JPWCC和ACC的调查人员是长期合作者，负责每个项目。西南肿瘤组淋巴瘤委员会的临床和病理资源也被整合到这个计划中。项目包括： 研究项目1：靶向极光激酶在侵袭性B细胞非霍奇金淋巴瘤， 项目2：优化氧化还原调节作为NHL的治疗策略。 项目3：增强蛋白酶体抑制剂在NHL中的活性。 项目4：淋巴瘤引发细胞的表征。

This Lymphoma SPORE application from the James P. Wilmot Cancer Center (JPWCC), University of Rochester, and the Arizona Cancer Center (ACC), University of Arizona provides a broad based, translational research program studying several major unresolved issues in the lymphoma biology. Specifically the projects will focus on several novel, targeted therapeutic agents either in development or approved for the treatment of three of the most common non-Hodgkin's lymphomas, namely diffuse large B-cell, follicular and mantle cell lymphoma. We will initially seek to elucidate mechanisms of action and/or resistance both in vitro, and in carefully developed model systems; then pilot clinical trials with an emphasis on correlative studies will be designed and conducted to validate these mechanisms. Investigators at the JPWCC and the ACC, long-time collaborators, lead each of the programs. The clinical and pathologic resources of the Lymphoma Committee of the Southwest Oncology Group are also integrated into this program. Projects include: Research Project 1: Targeting Aurora Kinase in Aggressive B-cell non-Hodgkin's Lymphoma, Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL. Project 3: Potentiating Proteasome Inhibitor Activity in NHL. Project 4: Characterization of Lymphoma-lnitiating Cells.